Lovastatin reversed the enhanced sphingomyelin caused by 27-hydroxycholesterol in cultured vascular endothelial cells

Biochemistry and Biophysics Reports

Volumn 5, Issue , 2016, Pages 127-133

  Zhou, Qi ^a   Luo, Allan ^b   Kummerow, Fred A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

27 hydroxycholesterol CTP: phosphocholine cytidylyltransferase; Lovastatin; Phosphatidylcholine; Sphingomyelin

Indexed keywords

26 HYDROXYCHOLESTEROL; CHOLESTEROL; CHOLINE PHOSPHATE CYTIDYLYLTRANSFERASE; MEVALONIC ACID; MEVINOLIN; OXYSTEROL; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN;

ARTICLE; CELL MEDIATED CYTOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; MTT ASSAY; VASCULAR ENDOTHELIUM;

EID: 84949293116     PISSN: None     EISSN: 24055808     Source Type: Journal    
DOI: 10.1016/j.bbrep.2015.11.024     Document Type: Article

References (39)

1. Brown A.J., Jessup W. Oxysterols and atherosclerosis. Atherosclerosis 1999, 142:1-28.
2. Umetani M., Ghosh P., Ishikawa T., Umetani J., Ahmed M., Mineo C., Shaul P.W. The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. Cell Metab. 2014, 20:172-182.
3. Björkhem I., Eggertsen G. Genes involved in initial steps of bile acid synthesis. Curr. Opin. Lipidol. 2001, 12:97-103.
4. Babiker A., Andersson O., Lund E., Xiu R.J., Deeb S., Reshef A., et al. Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hyroxylase mechanism comparision with high density lipoprotein-mediated reverse Cholestrol Transport: Comparison with high density lipoprotein-mediated reverse cholesterol transport. J. Biol. Chem. 1997, 272:26253-26261.
5. Kummerow F.A., Cook L.S., Wasowicz E., Jelen H. Changes in the phospholipid composition of the arterial cell can result in severe atherosclerotic lesions. J. Nutr. Biochem. 2001, 12:602-607.
6. ++ content in cultured smooth muscle cells. Biomed. Env. Sci. 1997, 10:369-376.
7. Kumar N., Singhal O.P. Cholesterol oxides and atherosclerosis: a review. J. Sci. Food Agric. 1991, 55:497-510.
8. Zhou Q., Jimi S., Smith T.L., Kummerow F.A. The effect of 25-hydroxycholesterol on accumulation of intracellular calcium. Cell Calcium 1991, 12:467-478.
9. Van Deenen L.L.M. Topology and dynamics of phospholipids in membranes. FEBS Lett. 1981, 123:3-15.
10. Shah D.O., Schulman J.H. Interaction of calcium ions with lecithin and sphingomyelin monolayers. Lipids 1967, 2:21-27.
11. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
12. Kavalipati N., Shah J., Ramakrishan A., Vasnawala H. Pleiotropic effects of statins. Indian J. Endocrinol. Metab. 2015, 19:554-562.
13. Zhou Q., Kummerow F.A. Antioxidative effects of lovastatin in cultured human endothelial cells. J. Nutr. Biochem. 2002, 13:200-208.
14. Dietzen D.J., Page K.L., Terzloff T.A., Bohrer A., Turk J. Inhibition of 3-hydroxy-3methylglutaryl coenzyme A (HMG CoA) reductuse blunts factor VIIa/tissue factor and prothrombinase activities via effects on membrane phosphatidylserine. Arter. Thromb. Vasc. Biol. 2007, 27:690-696.
15. Chen H., Born E., Mathur S.N., Field F.J. Cholesterol and sphingomyelin synthesis are regulated independently in cultured human intestinal cells, CaCo-2: role of membrane cholesterol and sphingomyelin content. J. Lipid Res. 1993, 34:2159-2167.
16. 2 and effects of simvastatin treatment. Atherosclerosis 2008, 36:25-33.
17. Snowden S.G., Grapov D., Settergren M., D'Alexandri F.L., HaeggstrÖm J.Z., Fiehn O., et al. High-dose simvastatin exhibits enhanced lipid-lowering effects relative to simvastatin/ezetimibe combination therapy. Circ. Cardiovasc. Genet. 2014, 7:955-964.
18. Uyuklu M., Meiselman H.J., Baskurt O.K. Effect of decreases plasma cholesterol by atrovastatin treatment on erthrocyte mechanical properties. Clin. Hemorheol. Microcirc. 2007, 336:25-33.
19. Bergheanu S.C., Reijmers T., Zwinderman A.H., Bobeldijk I., Ramaker R., A.H.Liem, et al. Lipidomic approach to evaluate rosuvastatin and atrovastatin at various dosages: investigating differential effects among statins. Curr. Med. Res. Opin. 2008, 24:2477-2487.
20. Roglans N., Verd J.C., Peris C., Alegret M., Vázquez M., Adzet T., et al. High doses of atorvastatin and induce key enzymes involved in VLDL production. Lipids 2002, 37:445-454.
21. Alegret M., Verd J.C., Díaz C., Hernández G., Adzet T., Sánchez R.M., et al. Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits. Eur. J. Pharmacol. 1998, 347:283-291.
22. Glick D., Fell B.F., Sjølin K.E. Spectrophotometric determination of nanogram amounts of total cholesterol in microgram quantities of tissue or microliter volumes of serum. Anal. Chem. 1964, 36:1119-1121.
23. Skipsli V.P., Peterson R.F., Barclay M. Quantitative analysis of phospholipids by thin-layer chromatography. Biochem. J. 1964, 90:374-378.
24. 2 and 5-lipoxygenase. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281:L108-L118.
25. 2-ceramide and its relationship to apoptosis. Mol. Pharmacol. 2002, 62:1065-1075.
26. Vivekananda J., Smith D., King R.J. Sphingomyelin metabolites inhibit sphingomyelin synthase and CTP: phosphocholine cytdylyltransferase. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281:L98-L107.
27. Murate T., Susuki M., Hattori M., Takagi A., Kojima T., Tanizawa T., et al. Up-regulation of acid sphinhomyelinase during retinoic acid-induced myeloid differentiation of NB4, a human acute promyelocytic leukemia cell line. J. Biol. Chem. 2002, 277:9936-9943.
28. Han R., W.Q.Wu, X.P.Wu, C.Y.Liu Effect of total flavonoids from the seeds fo Astragali complanati on natural killer cell function. J. Ethnopharmacol. 2015, 173:157-165.
29. Koval M., Pagano R.E. Intracellular transport and metabolism of sphingomyelin. Biochim. Biophys. Acta 1991, 1082:113-125.
30. 2 cells. Clin. Ther. 1994, 16:200-208.
31. Stoffel W. Functional analysis of acid and neutral sphingomyelinases in vitro and in vivo. Chem. Phys. lipids 1999, 102:107-121.
32. Chatterjee S., Ghosh N. Neutral sphingomyelinase from human urine. Purification and preparation of monospecific antibodies. J. Biol. Chem. 1989, 264:12554-12600.
33. Chatterjee S. Neutral sphingomyelinase: past, present and future. Chem. Phys. Lipids 1999, 102:79-96.
34. Zhou Q., Band M.R., Hernandez A., Liu Z.L., Kummerow F.A. 27-Hydroxycholesterol inhibits neutral sphingomyelinase in cultured human endothelial cells. Life Sci. 2004, 75:1567-1577.
35. Gehrig K., Lagace T.A., Ridgway N.D. Oxysterol activation of phosphatidylcholine synthesis involves CTP:phosphocholine cytidylyltransferase alpha translocation to the nuclear envelope. Biochem. J. 2009, 418:209-217.
36. Ng T.W., Ooi E.M., Watts G.F., Chan D.C., Weir J.M., Meikle P.J., Barrett P.H. Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome. J. Clin. Endocrinol. Metab. 2014, 99:E2335-E2340.
37. Hara A., Taketomi T. Characterization and change of phospholipids in the aorta of Watanabe hereditable hyperlipidemic rabbit. Jpn. J. Exp. Med. 1990, 60:311-318.
38. Spence M.W., Callahan J.W. Sphingomyelin-cholesterol lipidoses: the Niemann-Pick group of diseases. The Metabolic Basis of Inherited Disease 1989, Vol. 2:1655-1676. McGraw-Hill, New York, NY.
39. ++ uptake and lipid content in cultured human arterial smooth muscle cells treated with 26-hydroxycholesterol. Artery 1994, 21:182-192.